Authors
Loading...
Analysis reveals the R&D tax credit lacks cost-effectiveness across firm categories, indicating design improvements are needed.
Janet W. Tillinger (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: